Overview

Corporate Profile

Laboratory Corporation of America® Holdings, an S&P 500 company, is the world’s leading healthcare diagnostics company, providing comprehensive clinical laboratory services through LabCorp Diagnostics, and end-to-end drug development support through Covance Drug Development. LabCorp is a pioneer in commercializing new diagnostic technologies and is improving people’s health by delivering the combination of world-class diagnostics, drug development and knowledge services. With combined revenue pro... More >>

Recent NewsMore >>
DateTitle 
08/24/15Covance Announces Pioneering Agreement with Leading Pharmaceutical Company for Worldwide Portfolio-Level Clinical Trial Monitoring
Xcellerate® Monitoring sets new standard for risk-based monitoring of clinical trials PRINCETON, N.J.--(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) today announced that Covance Drug Development (Covance) has received a multi-year award from a leading pharmaceutical company to use Covance’s Xcellerate® platform as an exclusive central monitoring solution for their worldwide clinical trials p... 
Printer Friendly Version
08/24/15LabCorp Furthers Leadership in Personalized Medicine in Cancer by Offering Innovative VistaSeq® Hereditary Cancer Panel
VistaSeq strategically focuses on actionable genetic mutations to identify patients with increased risk of many commonly diagnosed cancers BURLINGTON, N.C.--(BUSINESS WIRE)--Aug. 24, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the nationwide availability of its VistaSeq Hereditary Cancer Panel, a novel, 27-gene panel designed to identify patients with increased risk of breast, ovarian, melanoma, pancreatic... 
Printer Friendly Version
07/28/15LabCorp Announces New Covance Leadership
Deborah Keller to succeed Joe Herring as Covance Drug Development CEO BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH) today announced that Deborah Keller will succeed Joseph Herring as Chief Executive Officer of Covance Drug Development (Covance). Mr. Herring will retire on July 31 after more than a decade as CEO. Ms. Keller joined Covance in 1987 and has held senior l... 
Printer Friendly Version
07/28/15Laboratory Corporation of America® Holdings Announces Record 2015 Second Quarter Results and Raises 2015 Adjusted EPS Guidance
Q2 Net revenue of $2.2 billion, up 46% over last year Q2 Diluted EPS of $1.64; Q2 Adjusted EPS of $2.09, up 14% over last year Q2 Free Cash Flow of $328 million, up 106% over last year 2015 Adjusted EPS guidance raised to $7.75 - $8.00 from $7.55 - $7.90 BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 28, 2015-- Laboratory Corporation of America® Holdings (LabCorp® or the “Company”) (NYSE... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
LH (Common)
ExchangeNYSE
Price$119.61
Change Stock is Down 0.21
Intraday High$120.28
Intraday Low$118.86
Volume717,592
Data as of 08/28/15
4:02 p.m. ET
Minimum 20 minute delay
Refresh quote

Reports & Performance

2014 Annual Report

2013 Annual Report

2012 Annual Report

2011 Annual Report

2010 Annual Report

2009 Annual Report

2008 Annual Report

2007 Annual Report

2006 Annual Report

Latest Earnings Release